FBRX
Forte Biosciences, Inc.
1W: +6.2%
1M: -7.4%
3M: -10.1%
YTD: +11.7%
1Y: +317.4%
3Y: +7.2%
5Y: -96.0%
$26.38
+0.66 (+2.57%)
After Hours: $26.00 (-0.38, -1.44%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$10.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$330.5M
52W Range4.9-35.62
Volume301,008
Avg Volume204,784
Beta3.21
Dividend—
Analyst Ratings
Company Info
CEOPaul A. Wagner
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-13
Websitefortebiorx.com
3060 Pegasus Park Drive
Dallas, TX 75247
US
Dallas, TX 75247
US
310 618 6994
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX)
12 Health Care Stocks Moving In Wednesday's After-Market Session
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Riley Antony A | A-Award | 90,000 | $29.66 | 2026-01-12 |
| Riley Antony A | A-Award | 60,000 | — | 2026-01-12 |
| Wagner Paul A. | A-Award | 270,000 | $29.66 | 2026-01-12 |
| Wagner Paul A. | A-Award | 180,000 | — | 2026-01-12 |
| Wagner Paul A. | M-Exempt | 1,250 | — | 2026-01-01 |